Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study
Publication
, Conference
Lancet, JE; Ravandi, F; Ritchie, EK; Sayar, H; Strickland, SA; Schiller, GJ; Vey, N; Erba, HP; Pigneux, A; Horst, H-A; Recher, C; Odenike, O ...
Published in: BLOOD
December 3, 2015
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Lancet, J. E., Ravandi, F., Ritchie, E. K., Sayar, H., Strickland, S. A., Schiller, G. J., … Stuart, R. K. (2015). Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.
Lancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Stephen A. Strickland, Gary J. Schiller, Norbert Vey, et al. “Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.
Lancet JE, Ravandi F, Ritchie EK, Sayar H, Strickland SA, Schiller GJ, et al. Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study. In: BLOOD. AMER SOC HEMATOLOGY; 2015.
Lancet, Jeffrey E., et al. “Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study.” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.
Lancet JE, Ravandi F, Ritchie EK, Sayar H, Strickland SA, Schiller GJ, Vey N, Erba HP, Pigneux A, Horst H-A, Recher C, Odenike O, Carella A-M, Selleslag D, Kell J, Krug U, Page L, DeVault A, Hwang S, Craig AR, Stuart RK. Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study. BLOOD. AMER SOC HEMATOLOGY; 2015.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology